Network Diffusion Modeling Explains Longitudinal Tau PET Data

Network Diffusion Modeling Explains Longitudinal Tau PET Data

Alzheimer's disease is associated with the cerebral accumulation of neurofibrillary tangles of hyperphosphorylated tau protein. The progressive occurrence of tau aggregates in different brain regions is closely related to neurodegeneration and cognitive impairment. However, our current understa...

Full description

Bibliographic Details
Main Authors:	Amelie Schäfer, Elizabeth C. Mormino, Ellen Kuhl
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2020-12-01
Series:	Frontiers in Neuroscience
Subjects:	tau PET Neuroimaging model calibration Alzheimer's disease network diffusion model
Online Access:	https://www.frontiersin.org/articles/10.3389/fnins.2020.566876/full

Similar Items

PET Imaging of Tau Pathology: Towards an affirmative diagnosis of Alzheimer’s and Tauopathies
by: Olga eJames, et al.
Published: (2015-03-01)

Evaluation of partial volume correction and analysis of longitudinal [18F]GTP1 tau PET imaging in Alzheimer's disease using linear mixed-effects models
by: Sandra M. Sanabria Bohórquez, et al.
Published: (2024-03-01)

Influence of common reference regions on regional tau patterns in cross-sectional and longitudinal [18F]-AV-1451 PET data
by: Christina B. Young, et al.
Published: (2021-11-01)

The relationships between neuroinflammation, beta-amyloid and tau deposition in Alzheimer’s disease: a longitudinal PET study
by: Rola Ismail, et al.
Published: (2020-05-01)

Tau PET correlates with different Alzheimer’s disease‐related features compared to CSF and plasma p‐tau biomarkers
by: Rik Ossenkoppele, et al.
Published: (2021-08-01)

Deep learning detection of informative features in tau PET for Alzheimer’s disease classification
by: Taeho Jo, et al.
Published: (2020-12-01)

Diagnostic and therapeutic targeting of pathological tau proteins in neurodegenerative disorders
by: Naruhiko Sahara, et al.
Published: (2024-02-01)

Imaging Aβ and tau in early stage Alzheimer’s disease with [18F]AV45 and [18F]AV1451
by: Azadeh Firouzian, et al.
Published: (2018-03-01)

Baseline [18F]GTP1 tau PET imaging is associated with subsequent cognitive decline in Alzheimer’s disease
by: Edmond Teng, et al.
Published: (2021-12-01)

Fully synthetic phosphorylated Tau181, Tau217, and Tau231 calibrators for Alzheimer’s disease diagnosis
by: Xinyu Li, et al.
Published: (2024-01-01)

Initial levels of β-amyloid and tau deposition have distinct effects on longitudinal tau accumulation in Alzheimer’s disease
by: Yue Cai, et al.
Published: (2023-02-01)

Based on Tau PET Radiomics Analysis for the Classification of Alzheimer’s Disease and Mild Cognitive Impairment
by: Fangyang Jiao, et al.
Published: (2023-02-01)

Optimizing quantification of MK6240 tau PET in unimpaired older adults
by: Theresa M. Harrison, et al.
Published: (2023-01-01)

Altered excitatory and inhibitory neuronal subpopulation parameters are distinctly associated with tau and amyloid in Alzheimer’s disease
by: Kamalini G Ranasinghe, et al.
Published: (2022-05-01)

Tau-PET and in vivo Braak-staging as prognostic markers of future cognitive decline in cognitively normal to demented individuals
by: Davina Biel, et al.
Published: (2021-08-01)

Associations between different tau-PET patterns and longitudinal atrophy in the Alzheimer’s disease continuum: biological and methodological perspectives from disease heterogeneity
by: Rosaleena Mohanty, et al.
Published: (2023-02-01)

Topographic staging of tau positron emission tomography images
by: Adam J. Schwarz, et al.
Published: (2018-01-01)

Elevated medial temporal lobe and pervasive brain tau‐PET signal in normal participants
by: Val J. Lowe, et al.
Published: (2018-01-01)

The relationship of insulin resistance and diabetes to tau PET SUVR in middle-aged to older adults
by: Gilda E. Ennis, et al.
Published: (2023-03-01)

Partial volume correction in longitudinal tau PET studies: is it really needed?
by: Alejandro Costoya-Sánchez, et al.
Published: (2024-04-01)

Multicenter <sup>18</sup>F-PI-2620 PET for In Vivo Braak Staging of Tau Pathology in Alzheimer’s Disease
by: Michael Rullmann, et al.
Published: (2022-03-01)

Visual reading for [18F]Florzolotau ([18F]APN-1607) tau PET imaging in clinical assessment of Alzheimer’s disease
by: Huan-Chun Lin, et al.
Published: (2023-05-01)

Higher levels of myelin are associated with higher resistance against tau pathology in Alzheimer’s disease
by: Anna Rubinski, et al.
Published: (2022-09-01)

Longitudinal associations of apathy and regional tau in mild cognitive impairment and dementia: Findings from the Alzheimer's Disease Neuroimaging Initiative
by: Pranitha Y. Premnath, et al.
Published: (2024-01-01)

Implication of tau propagation on neurodegeneration in Alzheimer’s disease
by: Daniel Lamontagne-Kam, et al.
Published: (2023-07-01)

Comparison of regional flortaucipir PET with quantitative tau immunohistochemistry in three subjects with Alzheimer’s disease pathology: a clinicopathological study
by: Michael J. Pontecorvo, et al.
Published: (2020-06-01)

FDG-PET hypermetabolism is associated with higher tau-PET in mild cognitive impairment at low amyloid-PET levels
by: Anna Rubinski, et al.
Published: (2020-10-01)

Associations between quantitative [18F]flortaucipir tau PET and atrophy across the Alzheimer’s disease spectrum
by: Tessa Timmers, et al.
Published: (2019-07-01)

Combining tau-PET and fMRI meta-analyses for patient-centered prediction of cognitive decline in Alzheimer’s disease
by: Davina Biel, et al.
Published: (2022-11-01)

Plasma p-tau181 Level Predicts Neurodegeneration and Progression to Alzheimer's Dementia: A Longitudinal Study
by: Yan-Li Wang, et al.
Published: (2021-09-01)

Compensating for choroid plexus based off-target signal in the hippocampus using 18F-flortaucipir PET
by: Daria Pawlik, et al.
Published: (2020-11-01)

Tau Filament Self-Assembly and Structure: Tau as a Therapeutic Target
by: Sebastian S. Oakley, et al.
Published: (2020-11-01)

Relationship of amyloid beta and neurofibrillary tau deposition in Neurodegeneration in Aging Down Syndrome (NiAD) study at baseline
by: DL Tudorascu, et al.
Published: (2020-01-01)

In vivo tau pathology is associated with synaptic loss and altered synaptic function
by: Emma M. Coomans, et al.
Published: (2021-02-01)

Untangling tau imaging
by: Victor L. Villemagne, et al.
Published: (2016-01-01)

Bayesian workflow for the investigation of hierarchical classification models from tau-PET and structural MRI data across the Alzheimer’s disease spectrum
by: Clyde J. Belasso, et al.
Published: (2023-10-01)

Tau-related white-matter alterations along spatially selective pathways
by: Qiuting Wen, et al.
Published: (2021-02-01)

Clinical Impact of PET With 18F-FDG and 11C-PIB in Patients With Dementia in a Developing Country
by: Andres Damian, et al.
Published: (2021-05-01)

Head-to-head comparison between plasma p-tau217 and flortaucipir-PET in amyloid-positive patients with cognitive impairment
by: Nidhi S. Mundada, et al.
Published: (2023-09-01)

Preliminary mechanistic insights of a brain-penetrant microtubule imaging PET ligand in a tau-knockout mouse model
by: Naresh Damuka, et al.
Published: (2022-07-01)